{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:01:53Z","timestamp":1788915713505,"version":"build-2803163510"},"reference-count":59,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Significant improvements have occurred for adolescent and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients following the widespread adoption of \u201cpediatric-inspired\u201d treatment regimens for AYA patients cared for in adult oncology settings. However, for AYA patients, aged 15 to 39, an outcomes gap remains in B-ALL, necessitating the incorporation of novel therapies into up-front treatment regimens. As a result, clinical trial enrollment remains the current standard of care for AYA B-ALL across disease subtypes when available and accessible. Currently, several up-front trials are looking to incorporate the use of inotuzumab, blinatumomab, and chimeric antigen receptor T-cell therapy into existing chemotherapy backbones for AYA patients, as well as tyrosine kinase inhibitors for both Philadelphia-positive (Ph+) and Ph-like B-ALL. In addition to ongoing attempts to improve up-front treatments by incorporating immunotherapy and targeted approaches, the increased use of next generation sequencing for measurable residual disease evaluation has led to superior risk-stratification and a decreased need to pursue consolidative hematopoietic stem cell transplantation during the first complete remission for many patients.<\/jats:p>","DOI":"10.1182\/hematology.2023000510","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:13:11Z","timestamp":1702048391000},"page":"573-580","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Acute lymphoblastic leukemia in young adults: which up-front treatment?"],"prefix":"10.1182","volume":"2023","author":[{"given":"John C.","family":"Molina","sequence":"first","affiliation":[{"name":"1 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Rotz","sequence":"additional","affiliation":[{"name":"2 Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"7","key":"2024111418053763400_hem2023000510C1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","article-title":"Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations","volume":"36","author":"Toksvang","year":"2022","journal-title":"Leukemia"},{"issue":"3 February","key":"2024111418053763400_hem2023000510C2","first-page":"204062072090353","article-title":"Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population","volume":"11","author":"Carobolante","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"2024111418053763400_hem2023000510C3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/bloodadvances.2017014944","article-title":"Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study","volume":"2","author":"Muffly","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"2024111418053763400_hem2023000510C4","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"14","key":"2024111418053763400_hem2023000510C5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2024111418053763400_hem2023000510C6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol"},{"issue":"8","key":"2024111418053763400_hem2023000510C7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2024111418053763400_hem2023000510C8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jnci\/djz019","article-title":"RE: a reappraisal of sex-specific cancer survival trends among adolescents and young adults in the United States","volume":"111","author":"Siegel","year":"2019","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"2024111418053763400_hem2023000510C9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clml.2020.07.017","article-title":"Comparison of two pediatric-inspired regimens to Hyper-CVAD in Hispanic adolescents and young adults with acute lymphoblastic leukemia","volume":"21","author":"Almanza-Huante","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024111418053763400_hem2023000510C10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2024111418053763400_hem2023000510C11","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1016\/S2352-3026(22)00371-4","article-title":"Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024111418053763400_hem2023000510C12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/hematology.2022000336","article-title":"New developments in ALL in AYA","volume":"2022","author":"Boissel","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2024111418053763400_hem2023000510C13","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"2024111418053763400_hem2023000510C14","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41375-023-01992-z","article-title":"Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia","volume":"37","author":"Hoshitsuki","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"2024111418053763400_hem2023000510C15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.26853","article-title":"Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"98","author":"Aldoss","year":"2023","journal-title":"Am J Hematol"},{"issue":"14","key":"2024111418053763400_hem2023000510C16","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"issue":"9","key":"2024111418053763400_hem2023000510C17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2024111418053763400_hem2023000510C18","first-page":"10016","article-title":"A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: second safety phase results from Children's Oncology Group AALL1732","volume":"41","author":"McNeer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024111418053763400_hem2023000510C19","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"2024111418053763400_hem2023000510C20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2024111418053763400_hem2023000510C21","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"2024111418053763400_hem2023000510C22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"issue":"suppl 2","key":"2024111418053763400_hem2023000510C23","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2022-171751","article-title":"Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network Trial","volume":"140","author":"Litzow","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024111418053763400_hem2023000510C24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"2024111418053763400_hem2023000510C25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2024111418053763400_hem2023000510C26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/MOH.0000000000000685","article-title":"Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia","volume":"28","author":"Qayed","year":"2021","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"2024111418053763400_hem2023000510C27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2024111418053763400_hem2023000510C28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2024111418053763400_hem2023000510C29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/hematology.2022000338","article-title":"Ph+ ALL in 2022: is there an optimal approach?","volume":"2022","author":"Wieduwilt","year":"2022","journal-title":"Hematology"},{"issue":"2","key":"2024111418053763400_hem2023000510C30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2024111418053763400_hem2023000510C31","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014from intensive chemotherapy combinations to chemotherapy-free regimens: a review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"2024111418053763400_hem2023000510C32","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-023-05241-2","article-title":"Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant\u2014review article","volume":"102","author":"Alghandour","year":"2023","journal-title":"Ann Hematol"},{"issue":"8","key":"2024111418053763400_hem2023000510C33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2018-04-841676","article-title":"Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group","volume":"132","author":"Roberts","year":"2018","journal-title":"Blood"},{"issue":"28","key":"2024111418053763400_hem2023000510C34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2020.10.013","article-title":"The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities","volume":"84","author":"Tran","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"17","key":"2024111418053763400_hem2023000510C35","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1182\/bloodadvances.2022007597","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL","volume":"6","author":"Aldoss","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2024111418053763400_hem2023000510C36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"2024111418053763400_hem2023000510C37","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"2024111418053763400_hem2023000510C38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2018-99-110221","article-title":"A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): dose-finding results from the part 1 safety phase","volume":"132","author":"Tasian","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024111418053763400_hem2023000510C39","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.26908","article-title":"High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed\/refractory acute lymphoblastic leukemia with Philadelphia-like fusions","volume":"98","author":"Aldoss","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2024111418053763400_hem2023000510C40","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"2024111418053763400_hem2023000510C41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/cancers15020374","article-title":"Optimizing molecular minimal residual disease analysis in adult acute lymphoblastic leukemia","volume":"15","author":"Della Starza","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"16","key":"2024111418053763400_hem2023000510C42","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2024111418053763400_hem2023000510C43","doi-asserted-by":"crossref","first-page":"e28929","DOI":"10.1002\/pbc.28929","article-title":"Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"68","author":"Rau","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2024111418053763400_hem2023000510C44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"issue":"13","key":"2024111418053763400_hem2023000510C45","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"2024111418053763400_hem2023000510C46","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"issue":"14","key":"2024111418053763400_hem2023000510C47","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"December","key":"2024111418053763400_hem2023000510C48","doi-asserted-by":"crossref","first-page":"782785","DOI":"10.3389\/fped.2021.782785","article-title":"Allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia: shifting indications in the era of immunotherapy","volume":"9","author":"Truong","year":"2021","journal-title":"Front Pediatr"},{"issue":"4","key":"2024111418053763400_hem2023000510C49","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first CR, and an autologous transplantation is less effective than conventional consolidation\/ maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2024111418053763400_hem2023000510C50","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-021-01213-5","article-title":"Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR","volume":"35","author":"Wieduwilt","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2024111418053763400_hem2023000510C51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"issue":"7","key":"2024111418053763400_hem2023000510C52","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2024111418053763400_hem2023000510C53","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"2024111418053763400_hem2023000510C54","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1200\/JCO.22.01985","article-title":"Cost of cancer in adolescents and young adults in the United States: results of the 2021 report by Deloitte Access Economics, commissioned by Teen Cancer America","volume":"41","author":"Parsons","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024111418053763400_hem2023000510C55","doi-asserted-by":"crossref","first-page":"pkaa025","DOI":"10.1093\/jncics\/pkaa025","article-title":"Late effects in survivors of adolescent and young adult acute lymphoblastic leukemia","volume":"4","author":"Muffly","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"20","key":"2024111418053763400_hem2023000510C56","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.20.03681","article-title":"Rethinking success in pediatric oncology: beyond 5-year survival","volume":"39","author":"Williams","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024111418053763400_hem2023000510C57","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/1055-9965.EPI-21-1388","article-title":"Long-term outcomes among adolescent and young adult survivors of acute leukemia: a surveillance, epidemiology, and end results analysis","volume":"31","author":"Berkman","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2024111418053763400_hem2023000510C58","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1038\/s41598-022-07703-5","article-title":"Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials","volume":"12","author":"Mittal","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"2024111418053763400_hem2023000510C59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11912-020-01011-9","article-title":"Identifying and meeting the needs of adolescents and young adults with cancer","volume":"23","author":"Jin","year":"2021","journal-title":"Curr Oncol Rep"}],"updated-by":[{"DOI":"10.1182\/hematology.2024e03","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000}}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/573\/2312864\/573molina.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/573\/2312864\/573molina.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T18:05:55Z","timestamp":1731607555000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/573\/506423\/Acute-lymphoblastic-leukemia-in-young-adults-which"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000510","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}